
Phase 3 OptIMMize-1 findings show sustained skin clearance, itch reduction, and quality-of-life improvements with risankizumab through 52 weeks.
Anaheim Hills, Calif. - The new topical immunomodulators (TIMs) such as pimecrolimus (Elidel) and tacrolimus (Protopic) will reverse the growing number of cases of adult atopic dermatitis, predicts Cheryl Effron, M.D., a dermatologist in Anaheim Hills, Calif.